Navigation Links
Anthera Announces Update Call Regarding Vial Problems
Date:12/9/2010

HAYWARD, Calif., Dec. 9, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and remediation plans relating to vial problems in the PEARL-SC clinical study. Conference Call Access:Date:

December 14, 2010Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

29519371The slides associated with the call can be accessed by logging into the live webcast at www.anthera.com.

To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 29519371. The audio replay will be available until December 21, 2010.  This conference call will be webcast live and archived on Anthera's website until December 14, 2011, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulat
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
2. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
3. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
4. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
5. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
6. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
7. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
10. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... ST. PAUL, Minn. , March 6, 2015 /PRNewswire/ ... benefit manager serving more than 26 million members, today ... and Drug Administration,s (FDA) approval of the first biosimilar ... U.S. Food and Drug Administration (FDA) approval of Sandoz,s ... of all cancer patients, is a major milestone in ...
(Date:3/6/2015)... 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... corporate overview at the 27th Annual ROTH Conference on ... was previously scheduled to present at 5:30 pm Pacific ... held at The Ritz-Carlton Hotel in Laguna ...
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
... Conn., Oct. 6 The Hedgeye Risk Management Healthcare team, led ... Conference Call, "Aging of America: Demographics of Demand and Profits in ... long tail of demographics, why 1994-2002 was so good, and why ... device demand, and the outlook for hip, knee, and spine device ...
... Oct. 6 Roxane Laboratories, Inc. announced today ... (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg ... Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. ... for immediate shipment to wholesalers and pharmacies nationwide. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Ticket Down is ... Levi's® Stadium in Santa Clara, California. This state-of-the-art ... hosted a plethora of exciting events. , The “Kick the ... his popular summer tour to the west coast and Levi’s ... facility will take place on August 29 and fans of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Follow ... as the pharmacokinetics of a drug refers to testing ... compound inside an organism. When toxicity studies are clubbed ... ADMET or ADME/Tox. Increasing focus on lowering costs and ... ADME-toxicology testing worldwide. The traditional drug development model uses ...
(Date:3/6/2015)... Parents need to start the discourse ... use disorders. School programs like DARE, or Drug Abuse ... or Narcotics Overdose Prevention and Education has already impacted ... News on Feb. 27th. As teens continue to ... drug prevention proponents are lobbying Florida to pass The ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... Washington, DC (PRWEB) March 06, 2015 ... the nation’s only comprehensive source for key trends and ... specialty spend, medical injectables. Executives from Magellan Rx Management ... Pharmacy Trend Report: Discover Your Hidden Specialty Drug Spend,” ... Atlantic Information Services, Inc. , Specialty drug spend makes ...
Breaking Medicine News(10 mins):Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... is due to intensive care overuse or underuse , FRIDAY, ... United States are nearly five times more likely to spend ... in England, finds a new study, and U.S. patients over ... the ICU when they die. , That,s the conclusion of ...
... Length of labor and intensity vary among ethnic groups, ... Asian women experience less labor pain than other women, ... influenced by many different factors but are difficult to ... Pamela Flood, of the anesthesia department at Columbia University, ...
... Oct. 30 Qualsec (OTC Bulletin Board: QLSZ), which ... has signed an agreement with Seamless Corporation (OTC Bulletin ... part of the arrangement, VitaminSpice products will sell through ... retail offerings and other products will be co-marketed in ...
... Therap Services is hosting its 4th annual National ... 2010. Therap provides electronic documentation and communication ... developmental disabilities. Therap complies and helps providers comply ... , Provider Administrators are senior positions such ...
... With the rapidly increasing problem of cardiovascular (CVD) disease ... raise awareness of risk factors. The European Society of ... adopt an integrated approach to CVD management, through important ... more prevalent in India and China than in all ...
... says former star major league pitcher , FRIDAY, Oct. 30 ... hand. In less than a second, it curves and then ... curveball, when thrown correctly, is one of baseball,s most daunting ... so great have sworn that the ball seems to have ...
Cached Medicine News:Health News:Patients More Likely to Die While in ICU in U.S. Than in England 2Health News:Asians Seem to Suffer Less During Childbirth 2Health News:VitaminSpice Signs MOU With Seamless Corp. for Sale of VitaminSpice Product Line on the Seamless Websites 2Health News:VitaminSpice Signs MOU With Seamless Corp. for Sale of VitaminSpice Product Line on the Seamless Websites 3Health News:Therap Services to Host Conference on Electronic Documentation, Electronic Signatures and Electronic Health Records for the Developmental Disabilities Community 2Health News:ESC events in Asia tackle management of diabetes and cardiovascular disease 2Health News:ESC events in Asia tackle management of diabetes and cardiovascular disease 3Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3
... Electronic Medical Office (EMO) truly built for ... the unique needs of your practice. The ... electronic record system (EMR, EHR, and EPR), ... a new level of efficiency and performance. ...
... This program module functions stand alone. ... of the ophthalmicsuite product. The ASC module ... used in ophthalmic surgical specialty. Cataract, cosmetic, ... module. The ASC forms are adapted to ...
... is the perfect solution to assist you in ... control of your practice through the creative use ... pencil. No more impatient clients waiting to see ... old patient records. No more illegible handwriting on ...
... patient care reports for cardiology and ... reporting and documentation tool, physicians can ... H&P, labs, medications, and procedural details. ... with an e-signature, and distributed at ...
Medicine Products: